Hogan Lovells represents Sesen Bio in public offering

Philadelphia, 6 June 2018 – Hogan Lovells advised Sesen Bio, Inc., a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, in an approximate US$46 million follow-on public offering led by Jefferies and Canaccord Genuity. Sesen Bio intends to use the net proceeds from this offering for, among other things, the clinical development of Vicinium™ for the treatment of high-grade non-muscle invasive bladder cancer and the development of commercial-scale manufacturing capabilities.

Philadelphia partner Steve Abrams led the Hogan Lovells team, which also included Steve Nicolai, John Siemann, John Sharrar, Susan Lee, Steve Kaufman, Mike Applebaum, and Henry Kahn.

About Hogan Lovells

Hogan Lovells is a leading global legal practice providing business-oriented legal advice and high-quality service across its exceptional breadth of practices to clients around the world.

“Hogan Lovells” or the “firm” is an international legal practice that includes Hogan Lovells US LLP and Hogan Lovells International LLP. For more information, see www.hoganlovells.com.


Back To Listing

Loading data